AEON Biopharma, Inc.
AEON
$0.466
-$0.0655-12.32%
| Weiss Ratings | AEON - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | C- | |||
| Rating Factors | AEON - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Good | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AEON - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 3.64 | |||
| Price History | AEON - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -27.19% | |||
| 30-Day Total Return | -90.41% | |||
| 60-Day Total Return | -96.60% | |||
| 90-Day Total Return | -98.78% | |||
| Year to Date Total Return | -98.82% | |||
| 1-Year Total Return | -99.92% | |||
| 2-Year Total Return | -99.94% | |||
| 3-Year Total Return | -99.93% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -99.92% | |||
| 52-Week Low % Change | 16.50% | |||
| Price | AEON - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $619.20 | |||
| 52-Week Low Price | $0.40 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Apr 11, 2024 | |||
| Valuation | AEON - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 4.91M | |||
| Enterprise Value | 17.85M | |||
| Price/Earnings (TTM) | 0.01 | |||
| Earnings Per Share (TTM) | 68.14 | |||
| Earnings Per Share Growth | -114.94% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.01 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.47 | |||
| Enterprise Value/EBITDA (TTM) | -0.64 | |||
| Enterprise Value/EBIT | -0.64 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | AEON - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 555.30K | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AEON - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 949 354 6499 | |||
| Address | 5 Park Plaza Irvine, CA 92614 | |||
| Website | www.aeonbiopharma.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | AEON - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | AEON - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -348.24% | |||
| Return on Equity | -- | |||
| Income Statement | AEON - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -27.73M | |||
| EBIT (TTM) | -27.82M | |||
| Net Income (TTM) | 42.01M | |||
| Net Income Avl. to Common (TTM) | 42.01M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 107.93% | |||
| EPS Diluted (TTM) | 68.14 | |||
| EPS Diluted Growth (Q YOY) | 106.82% | |||
| Balance Sheet | AEON - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 13.00K | |||
| Cash Per Share (Q) | $0.02 | |||
| Total Current Assets (Q) | 1.59M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -28.57M | |||
| Current Ratio (Q) | 0.112 | |||
| Book Value Per Share (Q) | -$51.43 | |||
| Total Assets (Q) | 3.14M | |||
| Total Current Liabilities (Q) | 14.15M | |||
| Total Debt (Q) | 12.96M | |||
| Total Liabilities (Q) | 31.71M | |||
| Total Common Equity (Q) | -28.57M | |||
| Cash Flow | AEON - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 15.15M | |||
| Net Change in Cash (TTM) | -5.15M | |||
| Levered Free Cash Flow (TTM) | -10.38M | |||
| Cash from Operations (TTM) | -20.29M | |||
